Skin Cancer
FDA accepts Ameluz PDT sNDA for superficial basal cell carcinoma, with strong phase 3 clearance data and a September 2026 decision deadline.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to Safusidenib for IDH1-Mutant Glioma
2
Bridging Before CAR T in Myeloma Should Aim For Deep Response, Not Just Stability
3
mRNA Vaccine Plus Pembrolizumab Yields RFS, DMFS Benefit in Resectable Melanoma
4
FDA Grants Fast Track to PLN-101095 Plus Pembrolizumab in Solid Tumors
5